CClinicalTrials.gg
CompletedNCT02318823Updated Sep 28, 2015

Effects of Beer (Alcohol) on Social Cognition

An interventional study of Beer (alcoholic) and Placebo (non-alcoholic beer) in Healthy, sponsored by University Hospital, Basel, Switzerland. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-28.

Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The present study aims to evaluate effects of beer (alcohol) on social cognition.

Read the detailed description

Alcohol is one of the most widely used recreational drugs and it is often used in social settings to enhance sociability. There are few data showing that acute alcohol consumption affects facial emotion recognition. However the acute effects of alcohol in social drinkers on different aspects of social cognition are largely unknown. In the present study, we will therefore evaluate effects of beer (alcohol) on social cognition. The study will include 60 subjects (30 male, 30 female) and use a placebo-controlled, crossover design with the two experimental conditions alcoholic beer (individually calculated amount aiming to achieve a blood-alcohol concentration of 0.4g/kg), and non-alcoholic beer (placebo). We primarily aim to evaluate whether beer (alcohol) affects the ability to correctly decode emotions in facial expressions using different facial emotion recognition Tasks. Additionally, appraisal of visual erotic stimuli following alcohol consumption will be evaluated. Subjective social and mood effects will be assessed using validated questionnaires. Blood samples will be collected to assess plasma levels of the "social hormone" oxytocin as well as blood alcohol levels to test possible associations with effects on emotional processing.

02

Conditions studied

  • Healthy

Keywords

  • social neuroscience
  • emotion
  • face recognition
  • empathy
  • beer
  • alcohol
  • social cognition
03

In context

Lead sponsor

University Hospital, Basel, Switzerland is the lead sponsor of 968 studies on the registry; 191 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Age between 18 and 50 years
  2. Sufficient understanding of the German language
  3. Subjects understand the procedures and the risks associated with the study
  4. Participants must be willing to adhere to the protocol and sign the consent form
  5. Participants must be willing to refrain from drinking alcohol in the evening preceding the study session
  6. Participants must be willing to abstain from excessive drinking and from taking illicit psychoactive drugs during the study.
  7. Participants must be willing not to eat or drink xanthine-containing liquids (such as coffee, black or green tea, red bull, chocolate) 3 h prior to the study session
  8. Participants must be willing not to drive a traffic vehicle or to operate machines for 3h after the sessions
  9. Women must have a negative pregnancy test at the beginning of each session.

Exclusion criteria

Exclusion Criteria:

  1. Chronic or acute medical condition.
  2. Current or previous personal history of psychotic or major affective disorder.
  3. Prior or current alcohol abuse, dangerous drinking behavior (>15 points in the AUDIT questionnaire).
  4. Family history of alcoholism (first-degree relative).
  5. Alcohol hypersensitivity
  6. Prior illicit drug use (except Tetrahydrocannabinol (THC)-containing products) more than 15 times or any time within the previous week.
  7. Use of medications that are contraindicated or interfere otherwise with the effects of the study (monoamine oxidase inhibitors, antidepressants, sedatives etc.)
  8. Pregnant or nursing women.
  9. Participation in another clinical trial (currently or within the last 30 days).
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Other
    Beer (alcoholic) followed by placebo (non-alcoholic)

    Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has two treatment conditions in the same subject.

    Other: Beer (alcoholic) · Other: Placebo (non-alcoholic beer)

  • Other
    Placebo (non-acoholic beer) followed by Beer (alcoholic)

    Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has two treatment conditions in the same subject.

    Other: Beer (alcoholic) · Other: Placebo (non-alcoholic beer)

Interventions

  • OtherBeer (alcoholic)

    Beer (individually calculated amount aiming to achieve a blood-alcohol-centration of 0.4g/kg)

  • OtherPlacebo (non-alcoholic beer)

    Non-alcoholic beer serves as Placebo.

06

What researchers measure

Primary outcomes

  1. Effect of beer (alcohol) on emotion recognition

    Time frame: 3 hours

Secondary outcomes

  1. Effect of beer (alcohol) on empathy and social behavior

    Time frame: 3 hours

  2. Subjective effects of beer (alcohol)

    Time frame: 3 hours

  3. Effect of beer (alcohol) on appraisal of visual erotic stimuli

    Time frame: 3 hours

  4. Effects of beer (alcohol) on plasma oxytocin

    Time frame: 3 hours

  5. Effect modulation by genetic polymorphisms

    Time frame: 3 hours

07

Study locations

1 site
  • University Hospital Basel
    Basel, Switzerland
08

References and documents

Publications

  • Dolder PC, Holze F, Liakoni E, Harder S, Schmid Y, Liechti ME. Alcohol acutely enhances decoding of positive emotions and emotional concern for positive stimuli and facilitates the viewing of sexual images. Psychopharmacology (Berl). 2017 Jan;234(1):41-51. doi: 10.1007/s00213-016-4431-6. Epub 2016 Sep 19. PubMed 27640999 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02318823
Lead sponsor
University Hospital, Basel, Switzerland
Responsible party
Sponsor
First posted
Dec 17, 2014
Start date
Dec 2014
Primary completion
Sep 2015
Completion
Sep 2015
Last update
Sep 28, 2015

Study contacts

Matthias E Liechti, MD, MAS
principal investigator · University Hospital, Basel, Switzerland

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion